01 marzo 2010

J&J Actualiza la Fase III A Randomized, Multicenter Yondelis Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With T.R.S.

A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)

Official title A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)

...